Biotech Industry Gearing Up For More Science, Less Hype

But it's still unclear which new approaches in human therapeutics will pay off big; cancer and neuroscience are among the contenders Despite the enormous amount of money invested in research and development of biotechnology-derived human therapeutics in the past two decades or so, biotech industry participants and observers say the future is still unclear. Only 21 biotech drugs have been released so far, and many of those are bioengineered versions of substances that have been known and used

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Only 21 biotech drugs have been released so far, and many of those are bioengineered versions of substances that have been known and used for a long time, such as insulin and human growth hormone. During this time the industry has experienced spectacular rises and falls, both scientifically and financially, often fueled by hype and unrealistic expectations.

Currently in the pipeline, however, is the next generation of biotech drugs. And these drugs will take advantage of the latest discoveries of how cells work, targeting previously uncharacterized receptors on the surface of cells or moving directly into the nucleus to turn specific genes off or on.

But much of this next generation is either still in the laboratory or just beginning clinical trials. And considerable debate emerges among biotech observers in government and industry concerning which areas of research will, from an entrepreneurial standpoint, be most profitably pursued.

Research activities in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Franklin Hoke

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide